Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (Nasdaq: GILD) reported second quarter 2026 revenues of $7.8 billion, up 10% year-over-year, with total product sales of $7.6 billion. Product sales excluding Veklury rose 10%, driven by HIV, Trodelvy and Livdelzi, while Veklury declined 81% to $23 million.
HIV revenue increased 12% to $5.7 billion, including Biktarvy up 7% to $3.8 billion and Descovy up 48% to $967 million. Trodelvy sales grew 26% to $457 million, while Cell Therapy fell 14% to $417 million. Diluted loss per share was $(8.45) and non-GAAP diluted loss per share was $(6.75), mainly reflecting $11.2 billion of acquired IPR&D expenses from the Arcellx, Tubulis and Ouro Medicines deals.
Cash, cash equivalents and marketable debt securities were $3.2 billion at June 30, 2026 versus $10.6 billion at year-end 2025, after $11.3 billion of acquisition-related outflows. Gilead updated 2026 guidance, slightly raising product sales excluding Veklury, cutting expected Veklury sales to about $300 million and reaffirming a full-year GAAP and non-GAAP loss per share including roughly $9.08 of IPR&D-related impact.
Gilead Sciences (Nasdaq:GILD) reported second quarter 2026 revenues of $7.8 billion, up 10% year-over-year, with total product sales of $7.6 billion. Product sales excluding Veklury rose 10% to $7.6 billion, led by HIV (+12% to $5.7 billion), including Biktarvy (+7% to $3.8 billion) and Descovy (+48% to $967 million), as well as Trodelvy (+26% to $457 million) and Livdelzi. Veklury sales fell 81% to $23 million.
Gilead recorded a diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75), mainly from $11.2 billion of acquired IPR&D expenses tied to Arcellx, Tubulis and Ouro Medicines. Operating cash flow was $3.6 billion. Full-year 2026 product sales guidance is now $30.1–$30.4 billion, with product sales excluding Veklury raised to $29.8–$30.1 billion and Veklury guidance cut to about $300 million. GAAP diluted loss per share is guided to $(3.75)–$(3.40) and non-GAAP diluted loss per share to $(0.65)–$(0.30).
Gilead Sciences (Nasdaq: GILD) reported that the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors are PD-L1–positive (CPS ≥10). A European Commission decision is anticipated later in 2026.
The recommendation is based on Phase 3 ASCENT-04/KEYNOTE-D19, where Trodelvy plus Keytruda showed a highly statistically significant progression-free survival benefit and a 35% reduction in risk of disease progression or death versus standard chemotherapy plus Keytruda. Gilead noted this would build on existing Trodelvy monotherapy approvals in metastatic TNBC.
Gilead Sciences (Nasdaq: GILD) will release its second quarter 2026 financial results and guidance on Tuesday, August 4, 2026, after the market close. Management will host a webcast at 4:30 p.m. Eastern Time to review results and provide a business update.
The live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. Gilead is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID-19 and cancer, headquartered in Foster City, California.
Gilead Sciences (Nasdaq: GILD) and Merck (NYSE: MRK) reported detailed Phase 3 ISLEND-1 and ISLEND-2 Week 48 results for the investigational once-weekly oral HIV regimen islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in virologically suppressed adults who switched from daily antiretroviral therapy.
According to Gilead and Merck, ISL/LEN was noninferior to BIKTARVY in ISLEND-1, with 0% vs 0.3% of participants having HIV-1 RNA ≥50 copies/mL, and noninferior to standard of care in ISLEND-2, with 0.3% vs 1.3% above this threshold. Overall safety, serious adverse events and discontinuations were generally low and similar to comparators, though ISLEND-2 showed a higher rate of treatment-related adverse events with ISL/LEN. CD4+ T-cell counts, lymphocyte counts and body weight remained stable, and ISLEND-2 participants reported higher treatment satisfaction and lower treatment burden. These data will support planned regulatory submissions; ISL/LEN remains investigational and not approved.
Gilead Sciences (Nasdaq: GILD) will present extensive new HIV research at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro from July 26-31. Key data include 52-week open-label extension results from the Phase 3 PURPOSE 1 and PURPOSE 2 PrEP trials of twice-yearly lenacapavir, showing continued high efficacy, very high adherence (96% and 92%) and a consistent safety profile with no new signals. PURPOSE 1 recorded zero HIV infections during the extension, while PURPOSE 2 reported one infection among participants continuing lenacapavir. Gilead and Merck (NYSE: MRK) will also present full Phase 3 ISLEND-1 and ISLEND-2 results on a once-weekly investigational islatravir/lenacapavir oral regimen, alongside multiple Biktarvy and long-acting pipeline studies. Gilead highlights progress on its global access strategy for twice-yearly lenacapavir PrEP, expanding its no-profit supply program target from 2 million to up to 3 million people through 2028 and reporting availability in 10 priority sub-Saharan African countries.
Gilead (Nasdaq:GILD) received U.S. FDA approval for Trodelvy as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy can be used alone in PD-(L)1–ineligible patients or with Keytruda/Keytruda Qlex in PD-L1 CPS ≥10 tumors.
Approval is based on Phase 3 ASCENT-03 and ASCENT-04 data, where Trodelvy-based regimens reduced risk of progression or death by 38% and 35% versus chemotherapy-based comparators and extended median duration of response to 12.2 vs 7.2 months and 16.5 vs 9.2 months.
Gilead (Nasdaq:GILD) received European Commission approval for Trodelvy as first-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who have not had prior systemic metastatic therapy and are not candidates for PD-1/PD-L1 inhibitors.
The decision, covering the EU plus Norway, Iceland and Liechtenstein, is based on Phase 3 ASCENT-03, where Trodelvy cut the risk of progression or death by 38% versus chemotherapy. Trodelvy is the first antibody-drug conjugate and first new first-line treatment option in 20 years in Europe for this patient group and carries a boxed warning for severe neutropenia and diarrhea.
Gilead (Nasdaq:GILD) announced that the U.S. FDA has accepted its sNDA for once-weekly oral Yeztugo (lenacapavir) 300‑mg as investigational PrEP for HIV prevention. The FDA set a PDUFA date of February 2, 2027. The filing is supported by PURPOSE 1 and PURPOSE 2 trial results showing high efficacy in diverse populations. If approved, it could become the first long-acting oral PrEP option. Yeztugo’s current injectable PrEP indication and boxed warning emphasize strict HIV testing to reduce resistance risk.
Gilead (NASDAQ:GILD) announced a donation of more than 2,000 vials of intravenous remdesivir to Uganda to support the current Ebola Bundibugyo virus disease (BVD) outbreak. The medicine is supplied under compassionate use and MEURI frameworks, with additional supply being prepared.
Gilead is also preparing to support requests from the Democratic Republic of the Congo, WHO and other partners for remdesivir and obeldesivir as part of regional Ebola BVD response and planned clinical trials. Remdesivir shows promising preclinical activity across filoviruses but is not approved for filovirus disease, and its safety and efficacy for Bundibugyo strain remain under study.